The cost of postoperative pancreatic fistula versus the cost of pasireotide: results from a prospective randomized trial. Ann Surg 2017; 265: 11-16.

Published: 1st March 2017

Authors: Ma LW , Dominguez-Rosado I, Gennarelli RL, Bach PB, Gonen M, D’Angelica M et al.


This study included 300 procedures. Pasireotide significantly reduced the rate of significant postoperative pancreatic fistula (9 versus 21 percent, P=0.006), but taking into account the cost of the medication, there was no significant reduction in mean overall hospital costs.

Pubmed Link

Your comments